Management Team

● B. S., Applied Polymer Chemistry, University of Science and Technology of China

● Ph.D., Organic and Polymer Chemistry, Michigan State University

● Post doc, Massachusetts General Hospital (MGH), Harvard Medical School
● Nearly 20 years of experience in ADC development (including the design and development of payload and linker, the development of conjugation process), holding dozens of international patents

● Main contributor to the development of 2 macromolecular drug conjugates and 2 ADCs

● B.S., Chemistry, University of Science and Technology of China
● Ph.D., Chemistry and Biochemistry, University of Colorado Boulder
● More than 10 years of experience in ADC bioanalysis, drug metabolism, and pharmacokinetics (DMPK)
● Extensive experience in quantitative and qualitative mass spectrometry for drug development
● Supported the bioanalysis of 6 ADC clinical drugs by using an innovative 2-in-1 technology platform

● B. S.& M.S., Chemistry, Peking University

● Ph.D., McGill University
● Postdoc, University of Montreal

● Postdoc, Queen's University

● More than 10 years of experience in pharmaceutical chemistry, incl. the design and synthesis of ADC-related toxins and linkers
● Led and participated in the development of several ADC projects involving different types of toxins and linkers

● B.S., Medical Microbiology, University College London

● Ph.D., Microbiological immunity, University College London
● Postdoc, University of Lowa
● More than 20 years of experience in human translational studies (author on over 30 peer-reviewed papers in high-impact journals)
● Led the development of novel antibody drug conjugate (ADC) that target acute myeloid ● leukemia and myelodysplastic syndrome.
● Drived proof-of-concept experiments for novel molecular targets and biomarkers through the development of immune cell-based assays

Founder, Chief Technology Officer

Vice President, Analysis

Senior Director, Chemistry

Senior Director, Biology